Advances in research of neonatal Fc receptor inhibitors in the treatment of autoimmune disease of the nervous system
10.3760/cma.j.cn113694-20230420-00300
- VernacularTitle:新生儿Fc受体抑制剂在神经系统自身免疫性疾病治疗中的研究进展
- Author:
Lina ZHU
1
;
Yao TANG
;
Sai WANG
;
Gege WANG
;
Ziyan GUO
;
Xinyu LIU
;
Mengkai GUO
;
Jun WU
Author Information
1. 郑州大学第一附属医院神经内科，郑州450052
- Keywords:
Autoimmune diseases of the nervous system;
Immunoglobulin G;
FcRn inhibitors
- From:
Chinese Journal of Neurology
2023;56(7):830-836
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune diseases of the nervous system are a group of diseases caused by the body′s immune system attacking its own nervous system, resulting in structural damage and functional impairment of the corresponding tissues. Interventional clearance of pathogenic auto-antibodies has been shown to be effective in reducing immune damage, inhibiting disease progression and improving prognosis through extensive basic research and long-term clinical practice. The neonatal Fc receptor (FcRn)-mediated circulating protection mechanism of IgG contributes to the long half-life and high plasma levels of IgG. FcRn inhibitors are able to target and block the binding of FcRn to IgG, accelerating IgG clearance and reducing IgG levels. Therefore, the use of FcRn inhibitors in the treatment of autoimmune diseases of the nervous system could theoretically help to accelerate the clearance of pathogenic IgG, achieve good clinical efficacy and have promising applications. Research in this area has made considerable progress in recent years and this article will review this.
